Hong Kong, November 16, 2026
Akeso, Inc. (HKEX: 9926.HK) has announced that China’s National Medical Products Administration (NMPA) has approved the supplemental New Drug Application (sNDA) for gumokimab, its internally developed interleukin-17A (IL-17A) monoclonal antibody, for the treatment of active ankylosing spondylitis (AS). This regulatory milestone expands gumokimab’s approved therapeutic indications in China and strengthens Akeso’s position in the biopharmaceutical market for autoimmune and inflammatory diseases. The approval makes active ankylosing spondylitis the drug’s second approved indication, following its approval in June 2026 for adults with moderate-to-severe plaque psoriasis.
Phase III Clinical Trial Demonstrates Positive Results
The NMPA approval is supported by positive findings from the pivotal Phase III registration study AK111-303, which evaluated gumokimab in patients with active ankylosing spondylitis. According to Akeso, the study achieved all its prespecified efficacy endpoints, demonstrating rapid, robust and sustained improvements in disease symptoms. Treatment with gumokimab significantly improved disease activity, physical function and patients’ quality of life. The clinical study also demonstrated consistent achievement of the key ASAS20 and ASAS40 response criteria, which are established measures used to evaluate improvements in ankylosing spondylitis symptoms and clinical outcomes. These findings support the therapeutic potential of gumokimab as an additional treatment option for patients requiring long-term management of this chronic inflammatory condition.
IL-17A Mechanism Targets Inflammatory Disease Pathways
Gumokimab (AK111) is a humanized monoclonal antibody designed to selectively bind to interleukin-17A (IL-17A), a pro-inflammatory cytokine involved in the development and progression of several autoimmune diseases. By targeting IL-17A and preventing its interaction with the IL-17 receptor A (IL-17RA), gumokimab is designed to inhibit downstream inflammatory signalling pathways. This mechanism is particularly relevant to ankylosing spondylitis, a chronic inflammatory disease that primarily affects the sacroiliac joints, spine and peripheral joints. In advanced cases, the condition can cause spinal deformity, reduced mobility and significant functional impairment, affecting patients’ everyday activities and quality of life. The approval highlights the continued development of targeted biologic therapies that address specific immune pathways associated with chronic inflammatory diseases.
Akeso Strengthens Its Autoimmune Disease Pipeline
Commenting on the clinical findings, Professor Rong Mu, principal investigator of the AK111-303 study and professor at Peking University Third Hospital, highlighted the potential benefits of gumokimab in addressing unmet medical needs among patients with ankylosing spondylitis. He noted that the positive Phase III findings demonstrated improvements in core clinical endpoints, pain, stiffness, physical function and quality of life. Dr. Michelle Xia, Founder, Chairwoman, President and Chief Executive Officer of Akeso, acknowledged the contributions of investigators, clinical research teams and participating patients in achieving the regulatory milestone. She also highlighted the company’s expanding portfolio of innovative therapies targeting autoimmune and inflammatory diseases. Akeso’s pipeline includes ebdarokimab (IL-12/IL-23) and gumokimab (IL-17A), which are commercially available, alongside manfidokimab (IL-4Rα), which is progressing through late-stage clinical development, and the investigational AK139 IL-4Rα/ST2 bispecific antibody.
Source: Akeso press release



